Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Status:
Not yet recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining
Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Collaborators:
Dongguan People's Hospital Fujian Cancer Hospital Fujian Provincial Hospital Huizhou Municipal Central Hospital Jieyang People's Hospital Zhangzhou manicipal hospital of Fujian Province